Maurie Markman, MD, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
Maurie Markman, MD, president of medicine and science at the Cancer Treatment Centers of America, discusses how management and treatment strategies in ovarian cancer have influenced other cancers and will continue to do so.
For example, Markman says that the development of platinum-based chemotherapies such as paclitaxel started in ovarian cancer. Over time, this development became increasingly important in other cancers and tumor types as well.
Five years ago, treatments from ovarian cancer were not being used in areas such as lung cancer, but currently, these effective chemotherapies, targeted therapies, and immunotherapies are being used in a number of cancer types for chronic management, Markman adds.
Combining Avutometinib With Defactinib Yields High Response Rates in LGSOC
March 22nd 2024In heavily pretreated patients with recurrent low-grade serous ovarian cancer, the combination of avutometinib plus defactinib showing promising results within the phase 2 ENGOT-ov60/GOG-3052/RAMP 201 trial.
Read More